(Alliance News) - Ixico PLC on Wednesday said that it has signed a contract with an existing client to provide imaging services for the extension study of their Huntington's disease Ph2b trial.
Ixico is a London-based precision analytics company delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and multiple sclerosis.
Ixico said the contract is worth "just under" GBP2 million, which will be delivered over the next four years. The company did not name the client.
Huntington's disease is a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities.
Chief Executive Officer Giulio Cerroni said: "This contract strengthens our order book, securing further visibility to future anticipated revenues. We have been working with this client for several years and I am delighted to be further deepening our long-term partnership as they pursue a treatment for this terrible neurological disease."
Shares in Ixico were untraded at 18.01 pence each in London early Wednesday. Over the past 12 months the stock is down 52%.
By Sophie Rose, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Ixico (IXI)